Monotherapy or in combination w/ insulin (w/ or w/o metformin) in patients w/ type 2 DM as adjunct to diet & exercise to improve glycemic control. In combination w/ metformin or a PPARγ agonist (ie, thiazolidinediones) in patients w/ type 2 DM to improve glycemic control as initial therapy or when the single agent alone, w/ diet & exercise, provides inadequate glycemic control. In combination w/ a sulfonylurea in patients w/ type 2 DM to improve glycemic control when treatment w/ the maximal tolerated dose of a single agent alone, w/ diet & exercise, provides inadequate glycemic control & when metformin is inappropriate due to contraindications or intolerance. In combination w/ metformin & a sulfonylurea or a PPARγ agonist (ie, thiazolidinediones) in patients w/ type 2 DM to improve glycemic control when dual therapy w/ these agents, w/ diet & exercise, provides inadequate glycemic control.
100 mg once daily. Patient w/ moderate renal impairment (GFR ≥30 to <45 mL/min) 50 mg once daily. Patient w/ severe renal impairment (GFR ≥15 to <30 mL/min) or w/ end-stage renal disease (GFR <15 mL/min), including those requiring hemodialysis or peritoneal dialysis 25 mg once daily.
Discontinue if hypersensitivity or bullous pemphigoid is suspected. Should not be used in patients w/ type 1 diabetes or for treatment of diabetic ketoacidosis. Reports of acute pancreatitis. Hypoglycemia in combination w/ insulin or a sulfonylurea. Assessment of renal function is recommended prior to treatment initiation & periodically thereafter. Patients w/ renal impairment. Patients w/ severe hepatic impairment (Child-Pugh score >9). Pregnancy. Should not be used by nursing mothers. Ped patients.
Sign Out
